A new study sheds light on the genetic causes of a range of neurodegenerative disorders, including ALS, Parkinson's disease, and Huntington's disease, and determines factors that impact the age of onset as well as disease severity.
Increased ceramide levels in the brain may be a unique feature of all types of Lewy body dementias, including LBD associated with Parkinson's disease.
Musical therapy can help to improve fine motor skills in patients with Parkinson's disease.
A majority of Parkinson's patients report a diminished sense of smell, which starts to occur a number of years before the onset of other symptoms. Researchers are exploring whether scent-processing neurons which connect the nose to the brain may play a role in the development of Parkinson's disease.
Bach1, a protein that blocks the expression of genes associated with neuroprotection, has been implicated in Parkison's disease. Researchers say blocking Bach1 slows the deterioration of brain cells in preclinical models of Parkinson's disease.
Some viral infections could increase intercellular spreading of protein aggregates associated with neurodegenerative disorders, increasing the risk for developing Alzheimer's, Parkinson's, and other neurodegenerative diseases.
In the early stages of neurodegenerative diseases, microglia consume glucose to a greater extent than previously believed. The findings may serve as a new biomarker for a range of neurodegenerative disorders.
A new, improved DBS technique that targets specific subpopulations of neurons in the globus pallidus with short bursts of stimulation shows promising results as a treatment for Parkinson's disease.
Researchers highlight some of the current strategies being pursued to help restore lost function and regenerate brain areas affected by Parkinson's disease.
Drugs that increase signaling of Sonic Hedgehog (Shh) can help suppress the involuntary movements associated with dopamine replacement therapy for those with Parkinson's disease.
Two new intranasal drugs slow inflammation and stop the spread of alpha-synuclein in mouse models of Parkinson's disease. The drug also improved gait and balance in the animals. If the results are able to be replicated in humans, researchers say the drugs could be hailed as a "remarkable advance" in the treatment of Parkinson's disease.